BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st

- Preferred equity investment led by Sixth Street and with participation from HealthCare Royalty, a

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-bre

- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-bre

BridgeBio will also share an oral presentation and four posters at the meeting highlighting quality

Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and lowers t

Canaccord Genuity analyst Whitney Ijem initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with

Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 27, 202

Citigroup analyst Eric Joseph initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Neutral

- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstr

New data demonstrating disease modifying effects across clinical outcomes, biomarkers, and functiona

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with

Evercore ISI Group analyst Cory Kasimov maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperfor

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.84) per share which missed the analy

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of b

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceut

Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with

Mizuho analyst Salim Syed reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and maintai

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with

RBC Capital analyst Luca Issi initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Outperf

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceut

BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceu

Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises t

BridgeBio Pharma shares Phase 3 trial update, but early data show progress for rare muscle disease t

- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA hig

BridgeBio's rare-disease pipeline draws investor attention as new therapies near regulatory fili

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and rais

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceut

Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and

Oppenheimer analyst Trevor Allred maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and

Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and

Evercore ISI Group analyst Cory Kasimov maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperfor

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(1.00) per share which missed the analy

Ten large-cap stocks sank last week as weak earnings, lowered guidance, analyst downgrades, and deal

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with

Oppenheimer analyst Trevor Allred maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and

Wells Fargo analyst Derek Archila maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and

BridgeBio stock rises after Phase 3 trial shows its drug helped children with achondroplasia grow fa

BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a biopharmaceu

Wells Fargo analyst Derek Archila maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and

The transaction is part of our strategy to lower interest expense, reduce dilution, and significantl

-- The transaction is intended to strengthen the balance sheet, lower interest expense, reduce dilut

- Preliminary unaudited Q4 and Full Year 2025 net Attruby® product revenue of $146.0 million and $36